Background Chagas’ disease is a condition caused by the protozoan Trypanosoma cruzi that affects millions of people, mainly in Latin America where it is considered endemic. The chemotherapy for Chagas disease remains a problem; the standard treatment currently relies on a single drug, benznidazole, which unfortunately induces several side effects and it is not successful in the cure of most of the chronic patients. In order to improve the drug armamentarium against Chagas’ disease, in the present study we describe the synthesis of the compound 3-chloro-7-methoxy-2-(methylsulfonyl) quinoxaline (quinoxaline 4) and its activity, alone or in combination with benznidazole, against Trypanosoma cruzi in vitro. Methodology/Principal Findings Quinoxaline 4 was found to be strongly active against Trypanosoma cruzi Y strain and more effective against the proliferative forms. The cytotoxicity against LLCMK2 cells provided selective indices above one for all of the parasite forms. The drug induced very low hemolysis, but its anti-protozoan activity was partially inhibited when mouse blood was added in the experiment against trypomastigotes, an effect that was specifically related to blood cells. A synergistic effect between quinoxaline 4 and benznidazole was observed against epimastigotes and trypomastigotes, accompanied by an antagonistic interaction against LLCMK2 cells. Quinoxaline 4 induced several ultrastructural alterations, including formations of vesicular bodies, profiles of reticulum endoplasmic surrounding organelles and disorganization of Golgi complex. These alterations were also companied by cell volume reduction and maintenance of cell membrane integrity of treated-parasites. Conclusion/Significance Our results demonstrated that quinoxaline 4, alone or in combination with benznidazole, has promising effects against all the main forms of T. cruzi. The compound at low concentrations induced several ultrastructural alterations and led the parasite to an autophagic-like cell death. Taken together these results may support the further development of a combination therapy as an alternative more effective in Chagas’ disease treatment.
Macedo AM, Machado CR, Oliveira RP, Pena SD (2004) Trypanosoma cruzi: genetic structure of populations and relevance of genetic variability to the pathogenesis of chagas disease. Mem Inst Oswaldo Cruz 1: 1–12.
[3]
Rassi Jr A, Rassi A, Marcondes-de-Rezende J (2012) American trypanosomiasis (Chagas disease). Infect Dis Clin North Am 26: 275–291.
[4]
Feldman AM, McNamara D (2000) Myocarditis. N Engl J Med Nov 343: 1388–1398.
[5]
Wilkinson SR, Kelly JM (2009) Trypanocidal drugs: mechanisms, resistance and new targets. Expert Rev Mol Med 29: 11–31.
[6]
Maya JD, Cassels BK, Iturriaga-Vásquez P, Ferreira J, Faúndez M, et al. (2007) Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host. Comp Biochem Physiol, Part A Mol Integr Physiol 146: 601–620.
[7]
Coura JR (2009) Present situation and new strategies for Chagas disease chemotherapy: a proposal. Mem. Inst. Oswaldo Cruz 104: 549–554.
[8]
Veiga-Santos P, Pelizzaro-Rocha KJ, Santos AO, Ueda-Nakamura T, Dias Filho BP, et al. (2010) In vitro anti-trypanosomal activity of elatol isolated from red seaweed Laurencia dendroidea. Parasitology 137: 1661–1670.
[9]
Izumi E, Ueda-Nakamura T, Dias Filho BP, Veiga Júnior VF, Nakamura CV (2011) Natural products and Chagas' disease: a review of plant compounds studied for activity against Trypanosoma cruzi. Nat Prod Rep 28: 809–823.
[10]
Leite Silva CMB, Garcia FP, Rodrigues JHS, Nakamura CV, Ueda-Nakamura T, et al. (2012) Synthesis, antitumor, antitrypanosomal and antileishmanial activities of benzo[4,5]canthin-6-ones bearing the N -(substituted benzylidene)-carbohydrazide and N-alkylcarboxamide groups at C-2. Chem Pharm Bull 60: 1372–1379.
[11]
Becerra MC, Gui？azú N, Hergert LY, Pellegrini A, Mazzieri MR, et al. (2012) In vitro activity of N-benzenesulfonylbenzotriazole on Trypanosoma cruzi epimastigote and trypomastigote forms. Exp Parasitol 131: 57–62.
[12]
Valdez RH, Tonin LT, Ueda-Nakamura T, Silva SO, Dias Filho BP, et al. (2012) In vitro and in vivo trypanocidal synergistic activity of N-butyl-1-(4-dimethylamino)phenyl-1,2,3,？4-tetrahydro-β-carboline-3-carboxamideassociated with benznidazole. Antimicrob. Agents Chemother 56: 507–512.
[13]
Ishikawa H, Sugiyama T, Kurita K, Yokoyama A (2012) Synthesis and antimicrobial activity of 2,3-bis(bromomethyl)quinoxaline derivatives. Bioorg Chem 41: 1–5.
[14]
Kim YB, Kim YH, Park JY, Kim SK (2004) Synthesis and biological activity of new quinoxaline antibiotics of echinomycin analogues. Bioorg Med Chem Lett 19: 541–544.
[15]
Font M, Monge A, Alvarez E, Cuartero A, Losa MJ, et al. (1997) Synthesis and evaluation of new Reissert analogs as HIV-1 reverse transcriptase inhibitors. 1. Quinoline and quinoxaline derivatives. Drug Des Discov 14: 305–332.
[16]
Espinosa A, Sosha AM, Ryke E, Rowley DC (2012) Antiamoebic properties of the actinomycete metabolites echinomycin A and tirandamycin A. Parasitol Res. 111: 2473–2477.
[17]
Barea C, Pabón A, Galiano S, Pérez-Silanes S, Gonzalez G, et al. (2012) Antiplasmodial and leishmanicidal activities of 2-cyano-3-(4-phenylpiperazine-1-carboxam？ido)quinoxaline 1,4-dioxide derivatives. Molecules 7: 9451–9461.
[18]
Estevez Y, Quiliano M, Burguete A, Cabanillas B, Zimic M, et al. (2011) Trypanocidal properties, structure-activity relationship and computational studies of quinoxaline 1,4-di-N-oxide derivatives. Exp Parasitol 127: 745–751.
[19]
Barrett MP, Croft SL (2012) Management of trypanosomiasis and leishmaniasis. Br Med Bull 104: 175–196.
[20]
Jeon YW, Suh YJ (2012) Synergistic apoptotic effect of celecoxib and luteolin on breast cancer cells. Oncol Rep 29: 812–825.
[21]
Park KS, Choi JJ, Kim WU, Min JK, Park S, et al. (2012) The efficacy of tramadol/acetaminophen combination tablets (Ultracet？) as add-on and maintenance therapy in knee osteoarthritis pain inadequately controlled by nonsteroidal anti-inflammatory drug (NSAID). Clin Rheumatol 31: 317–23.
[22]
Nahid P, Pai M, Hopewell PC (2006) Advances in the diagnosis and treatment of tuberculosis. Proc Am Thorac Soc 3: 103–110.
[23]
Simon V, Ho DD, Abdool Karim Q (2006) HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet 368: 489–504.
[24]
Loyse A, Wilson D, Meintjes G, Jarvis JN, Bicanic T, et al. (2012) Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis 54: 121–128.
[25]
Perez-Mazliah DE, Alvarez MG, Cooley G, Lococo BE, Bertocchi G, et al. (2012) Sequential combined treatment with allopurinol and benznidazole in the chronic phase of Trypanosoma cruzi infection: a pilot study. J Antimicrob Chemother 1: 1–14.
[26]
Sangi DP, Correa AG (2010) Microwave-assisted synthesis of nitroketene N,S-arylaminoacetals. J Braz Chem Soc 21: 795–799.
[27]
Venkatesh C, Singh B, Mahata PK, Ila H, Junjappa H (2005) Heteroannulation of nitroketene N,S-arylaminoacetals with POCl3: A novel highly regioselective synthesis of unsymmetrical 2,3-substituted quinoxalines. Org Lett 7: 2169–2172.
[28]
Camargo EP (1964) Growth and differentiation in Trypanosoma cruzi. I. Origin of metacyclic trypanosomes in liquid media. Rev Inst Med Trop Sao Paulo 6: 93–100.
[29]
Andrews NW, Colli W (1982) Adhesion and interiorization of Trypanosoma cruzi in mammalian cells. J Protozool 29: 264–269.
[30]
Brener Z (1962) Therapeutic activity and criterion of cure on mice experimentally infected with Trypanosoma cruzi. Rev Inst Med Trop S？o Paulo 4: 389–396.
[31]
Izumi E, Morello LG, Ueda-Nakamura T, Yamada-Ogatta SF, Dias Filho BPD, et al. (2008) Trypanosoma cruzi: Antiprotozoal activity of parthenolide obtained from Tanacetum parthenium (L.) Schultz Bip. (Asteraceae, Compositae) against epimastigote and amastigote forms. Exp Parasitology 118: 324–330.
[32]
Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Meth 16: 55–63.
[33]
Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27–55.
[34]
Zhao L, Au JL, Wientjes MG (2010) Comparison of methods for evaluating drug-drug interaction. Front Biosci 1: 241–249.
[35]
Chou TC (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2: 440–446.
[36]
Izumi E, Ueda-Nakamura T, Veiga VF, Pinto AC, Nakamura CV (2012) Terpenes from Copaifera demonstrated in vitro antiparasitic and synergic activity. J Med Chem 12: 2994–3001.
[37]
Menna-Barreto RF, Goncalves RL, Costa EM, Silva RS, Pinto AV, et al. (2009) The effects on Trypanosoma cruzi of novel synthetic naphthoquinones are mediated by mitochondrial dysfunction. Free Radic Biol Med 47: 644–653.
[38]
Lopes JN, Cruz FS, Docampo R, Vasconcellos ME, Sampaio MC, et al. (1978) In vitro and in vivo evaluation of the toxicity of 1,4-naphthoquinone and 1,2-naphthoquinone derivatives against Trypanosoma cruzi. Ann Trop Med Parasitol. 72: 523–531.
[39]
Schrijvers D (2003) Role of red blood cells in pharmacokinetics of chemotherapeutic agents. Clin Pharmacokinet. 42: 779–791.
[40]
Krantz A (1997) Red cell-mediated therapy: opportunities and challenges. Blood Cells Mol Dis 23: 58–68.
[41]
Pelizzaro-Rocha KJ, Tiuman TS, Izumi E, Ueda-Nakamura T, Dias Filho BP, et al. (2010) Synergistic effects of parthenolide and benznidazole on Trypanosoma cruzi. Phytomedicine 18: 36–39.
[42]
Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58: 621–681.
[43]
Chen L, Dou J, Su Z, Zhou H, Wang H, et al. (2011) Synergistic activity of baicalein with ribavirin against influenza A (H1N1) virus infections in cell culture and in mice. Antiviral Res. 91: 314–320.
[44]
Maldonado RA, Molina J, Payares G, Urbina JA (1993) Experimental chemotherapy with combinations of ergosterol biosynthesis inhibitors in murine models of Chagas' disease. Antimicrob Agents Chemother. 37: 1353–1359.
[45]
Benaim G, Sanders JM, Garcia-Marchán Y, Colina C, Lira R, et al. (2006) Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole. J Med Chem 49: 892–899.
[46]
Cencig S, Coltel N, Truyens C, Carlier Y (2012) Evaluation of benznidazole treatment combined with nifurtimox, posaconazole or AmBisome(？) in mice infected with Trypanosoma cruzi strains. Int J Antimicrob Agents 40: 527–532.
[47]
Urbina JA (2010) Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Trop 115: 55–68.
[48]
Vilchez-Larrea SC, Alonso GD, Schlesinger M, Torres HN, Flawiá MM, et al. (2011) Poly(ADP-ribose) polymerase plays a differential role in DNA damage-response and cell death pathways in Trypanosoma cruzi. Int J Parasitol 41: 405–416.
[49]
Reiners JJ, Kleinman M, Joiakim A, Mathieu PA (2009) The chemotherapeutic agents XK469 (2-{4-[(7-chloro-2-quinoxalinyl)oxy] phenoxy}propionic acid) and SH80 (2-{4-[(7-bromo-2-quinolinyl)oxy]phenoxy？}propionic acid) inhibit cytokinesis and promote polyploidy and induce senescence. J Pharmacol Exp Ther 328: 796–806.
[50]
Chaabane W, User SD, El-Gazzah M, Jaksik R, Sajjadi E, et al. (2013) Autophagy, Apoptosis, Mitoptosis and Necrosis: Interdependence Between Those Pathways and Effects on Cancer. Arch Immunol Ther Exp. 61: 43–58.
[51]
Schweichel JU, Merker HJ (1973) The morphology of various types of cell death in prenatal tissues. Teratology 7: 253–266.
[52]
Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, et al. (2008) Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 4: 151–175.
[53]
Bursch W, Karwan A, Mayer M, Dornetshuber J, Fr？hwein U, et al. (2008) Cell death and autophagy: cytokines, drugs, and nutritional factors. Toxicology 254: 147–157.
[54]
Fernandes MC, Da Silva EM, Pinto AV, De Castro SL, Menna-Barreto RF (2012) A novel triazolic naphthofuranquinone induces autophagy in reservosomes and impairment of mitosis in Trypanosoma cruzi. Parasitology 139: 26–36.
[55]
van der Vaart A, Reggiori F (2010) The Golgi complex as a source for yeast autophagosomal membranes. Autophagy 6: 800–801.
[56]
Levine B, Mizushima N, Virgin HW (2011) Autophagy in immunity and inflammation. Nature 20: 323–335.
